News

Leonard Zon, MD, honored by the American Society of Hematology for Outstanding Mentorship

The ASH Mentor Award recognizes hematologists who have excelled in mentoring trainees and colleagues.

Dana-Farber/Boston Children's nation’s #1 pediatric cancer program

U.S. News & World Report has named Dana-Farber/Boston Children’s Cancer and Blood Disorders Center the nation’s #1 pediatric cancer program in its new 2019-20 Best Children’s Hospitals rankings.

Katherine E. Warren, MD, joins Dana-Farber/Boston Children’s as Clinical Director for Pediatric Neuro-Oncology

Warren is an internationally recognized expert in pediatric neuro-oncology. Her work focuses on rational, pharmacokinetic-based drug development for children with brain tumors, and she is a leading innovator in developing new means of drug delivery.

Lynda M. Vrooman to present findings from Dana-Farber/Boston Children’s clinical trial that led to FDA approval of novel drug for treatment of ALL in young patients

Vrooman will share the abstract at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO).

Children with cancer wait an average of 6.5 years longer than adults to access new targeted drugs, finds study at Dana-Farber/Boston Children’s

Researchers call for expanding children’s access to experimental cancer therapies

Team led by Dana-Farber/Boston Children’s Kimberly Stegmaier receives SU2C Sharp Award from Stand Up To Cancer

Stand Up To Cancer (SU2C) announced on May 2 that a team led by Kimberly Stegmaier, MD, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, and Sarah Tasian, MD, Children's Hospital of Philadelphia, was awarded a two-year grant totaling $250,000. Their SU2C Sharp Award is titled: Precision combinatorial immunotherapeutic targeting of thymic stromal lymphopoietin receptor (TSLPR) signaling in pediatric and young adult CRLF2-rearranged ALL.

Researchers at Dana-Farber/Boston Children's and UMass Medical School optimize gene editing for sickle cell disease and beta thalassemia

Researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and the University of Massachusetts Medical School have developed a strategy to treat two of the most common inherited blood diseases, sickle cell disease and beta thalassemia, applying CRISPR-Cas9 gene editing to patients' own blood stem cells.

Scott Armstrong, MD, PhD, recognized by ISSCR for contributions to basic and translational research in hematological disorders

The International Society for Stem Cell Research (ISSCR) announced that Scott Armstrong, MD, PhD, is the recipient of its 2019 Tobias Award Lecture.

Dana-Farber/Boston Children's Brian D. Crompton, MD, awarded research grant by the Go4theGoal Foundation

The Go4theGoal Foundation (G4TG) recently awarded Brian Crompton, MD, of the Dana-Farber/Boston Children's Cancer and Blood Disorders Center, a $50,000 research grant.

Transplants from any donor, without toxicity?

Pre-treatment with an antibody-drug combination avoids side effects in mice; could substitute for current toxic regimens using chemotherapy or radiation